Atacicept · Trutakna, VT-001

What is Atacicept?

Atacicept-vymj is a TACI-Fc fusion protein that binds and blocks B cell activating factor (BAFF) and A Proliferation Inducing Ligand (APRIL), reducing their signaling and decreasing production of galactose-deficient IgA1.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Trutakna, VT-001

Drug type

Fusion protein

Targets

B cell activating factor (BAFF) (TNFSF13B), A Proliferation Inducing Ligand (APRIL) (TNFSF13)

Mechanism

Antagonist of B cell activating factor (BAFF) (TNFSF13B) and A Proliferation Inducing Ligand (APRIL) (TNFSF13)

Pathways

BAFF-mediated signaling, APRIL-mediated signaling

Therapy area

Immunology, Renal & urology

Developer

Vera Therapeutics Inc. (VERA)

FDA status

Approved as Trutakna (July 7, 2026), BLA761486 · FDA label

UNII

K3D9A0ICQ3

✅ FDA-approved uses

• Primary immunoglobulin A nephropathy (IgAN)

From the indications section of the FDA label (version of Aug 5, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Berger DiseaseIgA NephropathyIgA Nephropathy (IgAN)Renal and Urinary Disorders

Other drugs acting on TNFSF13B / TNFSF13

More from Vera Therapeutics

Sources

• FDA Purple Book
• FDA label (DailyMed)
• FDA label Trutakna (2026-08-05), indications
• ClinicalTrials.gov NCT04716231
• ClinicalTrials.gov NCT06674577

Updated Oct 3, 2026. Something wrong or missing? Report it on the VERA page.